belzutifan
Sponsor Merck & CO INC. · listed as MRK
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-10-28
As disclosedOct 28, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT05239728
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorMerck Sharp & Dohme LLC
Listed asMRK
Condition(s)Carcinoma, Renal Cell
All tracked catalysts for belzutifan
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-10-28 | READOUT | medium | NCT05239728 |
| 2026-10-29 | READOUT | medium | NCT04736706 |
| 2027-06-07 | READOUT | medium | NCT05899049 |
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More MRK catalysts